PepGen reports Q2 2026 results, DSMB recommends dosing escalation.
Biotech company PepGen reported financial results affirming long-term solvency. It announced positive breakthroughs in its DM1 trial, including a Data Safety Monitoring Board's recommendation to escalate dosing due to the drug's promising safety profile.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day